Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Founder, Chief Executive Officer, President and Director
Vice Chairman and Chief Business Officer
Vice President of Research and Development
Consulting Medical Director and Member of Clinical Advisory Board
Compensation as of Fiscal Year 2017.
Altor BioScience Corporation Key Developments
Oxis International Inc. Enter Co-Development Partnership Agreement with Altor Bioscience Corp
Jun 13 17
Oxis International Inc. announced that it has entered into a co-development partnership agreement with Altor BioScience Corp. (Altor) in which the companies will collaborate exclusively in the clinical development of a novel 161533 TriKE fusion protein for cancer therapies using Oxis' trispecific killer engager (TriKE) technology. Under the partnership, Oxis and Altor will conduct a first-in-man Phase 1 FDA human clinical trial of the 161533 TriKE for the treatment of hematologic malignancies.
Altor Bioscience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer
May 2 17
Altor BioScience Corporation announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15
(IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). The FDA’s Fast Track program is designed to expedite the development and review of drugs to treat serious conditions and fill unmet medical needs. ALT-803 is currently being evaluated in a Phase Ib/II clinical trial to investigate the safety and efficacy of intravesical ALT-803 in combination with BCG in adult patients with BCG-naïve NMIBC as well as a separate Phase II clinical trial to investigate the safety and efficacy of intravesical ALT-803 in combination with BCG in adult patients with BCG-unresponsive NMIBC. Results from the recently completed Phase Ib NMIBC study will be presented at the American Urological Association Annual Meeting in Boston on May 12, 2017. The FDA Fast Track designation will apply to clinical development of ALT-803 in combination with BCG for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, as well as for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) in patients with NMIBC.
Altor BioScience Corporation Presents at BioFlorida Conference Jacksonville 2016, Dec-11-2016
Oct 6 16
Altor BioScience Corporation Presents at BioFlorida Conference Jacksonville 2016, Dec-11-2016 . Venue: Hyatt Regency Jacksonville Riverfront, 225 E Coastline Dr., Jacksonville, FL 32202, United States. Speakers: Warren Marcus, Business Development/Scientist.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 27, 2017
March 8, 2017